- Home
- GLTO vs CELZ Comparison
GLTO vs CELZ Comparison
Compare GLTO & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- CELZ
- Stock Information
- Founded
- GLTO 2011
- CELZ 1998
- Country
- GLTO Denmark
- CELZ United States
- Employees
- GLTO N/A
- CELZ N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- CELZ Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- CELZ Health Care
- Exchange
- GLTO Nasdaq
- CELZ Nasdaq
- Market Cap
- GLTO 6.5M
- CELZ 5.5M
- IPO Year
- GLTO 2020
- CELZ N/A
- Fundamental
- Price
- GLTO $2.83
- CELZ $2.29
- Analyst Decision
- GLTO Buy
- CELZ
- Analyst Count
- GLTO 1
- CELZ 0
- Target Price
- GLTO $10.00
- CELZ N/A
- AVG Volume (30 Days)
- GLTO 719.8K
- CELZ 140.2K
- Earning Date
- GLTO 03-19-2025
- CELZ 05-09-2025
- Dividend Yield
- GLTO N/A
- CELZ N/A
- EPS Growth
- GLTO N/A
- CELZ N/A
- EPS
- GLTO N/A
- CELZ N/A
- Revenue
- GLTO N/A
- CELZ $11,000.00
- Revenue This Year
- GLTO N/A
- CELZ N/A
- Revenue Next Year
- GLTO N/A
- CELZ N/A
- P/E Ratio
- GLTO N/A
- CELZ N/A
- Revenue Growth
- GLTO N/A
- CELZ 22.22
- 52 Week Low
- GLTO $2.79
- CELZ $1.92
- 52 Week High
- GLTO $19.75
- CELZ $6.90
- Technical
- Relative Strength Index (RSI)
- GLTO 38.47
- CELZ 32.75
- Support Level
- GLTO $2.79
- CELZ $1.95
- Resistance Level
- GLTO $3.38
- CELZ $2.24
- Average True Range (ATR)
- GLTO 0.77
- CELZ 0.33
- MACD
- GLTO -0.17
- CELZ -0.07
- Stochastic Oscillator
- GLTO 2.88
- CELZ 5.63
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.